Global analysis on the mutations associated with multidrug-resistant urogenital mycoplasmas and ureaplasmas infection: a systematic review and meta-analysis.
Drug resistance
Mutation
Mycoplasma infections
Ureaplasma infections
Journal
Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152
Informations de publication
Date de publication:
10 Aug 2023
10 Aug 2023
Historique:
received:
04
06
2023
accepted:
03
08
2023
medline:
14
8
2023
pubmed:
11
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
The emergence of multidrug-resistant (MDR) strains of genital pathogens, notably Mycoplasma genitalium and Ureaplasma spp., constitutes a significant global threat today. The present study aimed to evaluate the prevalence and trend of changes in MDR mycoplasma and ureaplasma strains. An exhaustive search was performed across the ISI Web of Science, PubMed, Scopus, ScienceDirect, and Google Scholar databases to accumulate relevant studies without restrictions until April 2023. We used event rate and corresponding 95% confidence intervals to determine the frequency of resistance-related mutations and examine the trend of antibiotic resistance changes. The data from 27 studies, including 24,662 patients across 14 countries, were evaluated. Out of the total studies, 20 focused on M. genitalium infections, and five on Ureaplasma spp. The frequency of resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones in clinical strains of M. genitalium was 43.5%, 13.1%, and 18.6%, respectively. The prevalence of M. genitalium strains with double resistance and MDR was 11.0% and 17.4%, respectively. The incidence of both double-drug-resistant and MDR strains was higher in the World Health Organization (WHO) Western Pacific Region than in European and American populations. For Ureaplasma strains, resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones were 40.8%, 25.7%, and 90.3%, respectively. The rate of antibiotic resistance was higher in the African population compared to the European and WHO Western Pacific Regions. The rate of MDR Ureaplasma infections was 13.2%, with a higher incidence in the African population compared to the WHO Western Pacific and European regions. The proliferation and spread of MDR Mycoplasma and Ureaplasma strains present a significant public health challenge. The situation is indeed alarming, and the rising trend of MDR M. genitalium and MDR Ureaplasma infections suggests that therapies involving macrolides and fluoroquinolones may become less effective.
Sections du résumé
BACKGROUND
BACKGROUND
The emergence of multidrug-resistant (MDR) strains of genital pathogens, notably Mycoplasma genitalium and Ureaplasma spp., constitutes a significant global threat today. The present study aimed to evaluate the prevalence and trend of changes in MDR mycoplasma and ureaplasma strains.
METHODS
METHODS
An exhaustive search was performed across the ISI Web of Science, PubMed, Scopus, ScienceDirect, and Google Scholar databases to accumulate relevant studies without restrictions until April 2023. We used event rate and corresponding 95% confidence intervals to determine the frequency of resistance-related mutations and examine the trend of antibiotic resistance changes.
RESULTS
RESULTS
The data from 27 studies, including 24,662 patients across 14 countries, were evaluated. Out of the total studies, 20 focused on M. genitalium infections, and five on Ureaplasma spp. The frequency of resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones in clinical strains of M. genitalium was 43.5%, 13.1%, and 18.6%, respectively. The prevalence of M. genitalium strains with double resistance and MDR was 11.0% and 17.4%, respectively. The incidence of both double-drug-resistant and MDR strains was higher in the World Health Organization (WHO) Western Pacific Region than in European and American populations. For Ureaplasma strains, resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones were 40.8%, 25.7%, and 90.3%, respectively. The rate of antibiotic resistance was higher in the African population compared to the European and WHO Western Pacific Regions. The rate of MDR Ureaplasma infections was 13.2%, with a higher incidence in the African population compared to the WHO Western Pacific and European regions.
CONCLUSION
CONCLUSIONS
The proliferation and spread of MDR Mycoplasma and Ureaplasma strains present a significant public health challenge. The situation is indeed alarming, and the rising trend of MDR M. genitalium and MDR Ureaplasma infections suggests that therapies involving macrolides and fluoroquinolones may become less effective.
Identifiants
pubmed: 37563660
doi: 10.1186/s12941-023-00627-6
pii: 10.1186/s12941-023-00627-6
pmc: PMC10416482
doi:
Substances chimiques
Anti-Bacterial Agents
0
Fluoroquinolones
0
Tetracyclines
0
Macrolides
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
70Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Int J STD AIDS. 2016 Oct;27(11):928-37
pubmed: 27147267
Ann Intern Med. 2009 Aug 18;151(4):W65-94
pubmed: 19622512
Obstet Gynecol Clin North Am. 2014 Dec;41(4):615-27
pubmed: 25454994
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28827422
Oral Dis. 1997 May;3 Suppl 1:S141-8
pubmed: 9456678
PLoS One. 2017 Apr 13;12(4):e0175763
pubmed: 28407014
Sex Transm Dis. 2019 Apr;46(4):e35-e37
pubmed: 30676483
Clin Infect Dis. 2008 Dec 15;47(12):1546-53
pubmed: 18990060
Med Mal Infect. 2012 Sep;42(9):381-92
pubmed: 22975074
Exp Ther Med. 2016 Aug;12(2):1165-1170
pubmed: 27443698
Emerg Infect Dis. 2020 Aug;26(8):1870-1874
pubmed: 32687029
Antimicrob Resist Infect Control. 2020 Jan 23;9(1):19
pubmed: 31998474
Afr Health Sci. 2018 Dec;18(4):1202-1203
pubmed: 30766586
Sex Transm Dis. 2017 Aug;44(8):457-462
pubmed: 28703723
J Oral Pathol Med. 2017 Sep;46(8):649-656
pubmed: 28295632
Open Forum Infect Dis. 2020 Jul 13;7(8):ofaa291
pubmed: 32782911
PLoS One. 2018 Jun 8;13(6):e0198355
pubmed: 29883482
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5
pubmed: 12499185
Int J STD AIDS. 2022 Mar;33(4):385-390
pubmed: 35094623
Front Microbiol. 2022 Aug 01;13:914464
pubmed: 35979479
Clin Infect Dis. 2009 Jun 15;48(12):1649-54
pubmed: 19438399
J Clin Pathol. 2014 Sep;67(9):817-20
pubmed: 24982440
Lancet. 1981 Jun 13;1(8233):1288-91
pubmed: 6112607
Int J Antimicrob Agents. 2009 Oct;34(4):295-303
pubmed: 19540725
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
Clin Microbiol Rev. 2011 Jul;24(3):498-514
pubmed: 21734246
Emerg Infect Dis. 2015 Jun;21(6):1062-4
pubmed: 25988775
Clin Microbiol Rev. 2005 Oct;18(4):757-89
pubmed: 16223956
J Clin Lab Anal. 2018 Jan;32(1):
pubmed: 28345794
Nat Rev Urol. 2017 Mar;14(3):139-152
pubmed: 28072403
Sex Transm Dis. 2019 Jan;46(1):18-24
pubmed: 29979336
Clin Infect Dis. 2017 Jul 15;65(2):332-335
pubmed: 28379472
Front Microbiol. 2021 Oct 08;12:724935
pubmed: 34690966
Emerg Infect Dis. 2016 Sep;22(9):1677-9
pubmed: 27533360
Clin Infect Dis. 2015 Nov 1;61(9):1389-99
pubmed: 26240201
J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1650-1656
pubmed: 27505296
Infect Drug Resist. 2017 Sep 01;10:283-292
pubmed: 28979150
Diagn Microbiol Infect Dis. 2023 Feb;105(2):115854
pubmed: 36436311
J Infect Chemother. 2012 Jun;18(3):414-8
pubmed: 22370921
Infection. 2012 Jun;40(3):239-62
pubmed: 22460782
Curr Drug Targets Infect Disord. 2005 Sep;5(3):263-71
pubmed: 16181145
Sex Transm Infect. 2018 Feb;94(1):14-20
pubmed: 28717050
Lancet Infect Dis. 2020 Nov;20(11):1302-1314
pubmed: 32622378
Sex Transm Infect. 2018 Feb;94(1):9-13
pubmed: 28717051
Antimicrob Agents Chemother. 2008 Feb;52(2):742-4
pubmed: 18025113
BMJ Open. 2022 Dec 7;12(12):e066368
pubmed: 36600371
Int J STD AIDS. 2020 Mar;31(3):190-197
pubmed: 32000587
Diagn Microbiol Infect Dis. 2016 Sep;86(1):115-7
pubmed: 27342785
Access Microbiol. 2021 Apr 9;3(4):000221
pubmed: 34151172
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):591-595
pubmed: 33029766
Int J Antimicrob Agents. 2020 Apr;55(4):105911
pubmed: 31991219
BMC Infect Dis. 2014 Mar 28;14:171
pubmed: 24679107
PLoS One. 2019 Feb 11;14(2):e0212131
pubmed: 30742669
Zh Mikrobiol Epidemiol Immunobiol. 2003 Jul-Aug;(4):81-5
pubmed: 12966887
BMC Microbiol. 2012 May 30;12:88
pubmed: 22646228
Antibiotics (Basel). 2021 Aug 10;10(8):
pubmed: 34439012
BMC Infect Dis. 2015 Feb 03;15:40
pubmed: 25645440
J Infect Chemother. 2012 Jun;18(3):313-7
pubmed: 22020630
Expert Rev Anti Infect Ther. 2010 Jan;8(1):59-70
pubmed: 20014902
J Antimicrob Chemother. 2014 Sep;69(9):2376-82
pubmed: 24894419
J Med Microbiol. 2019 Feb;68(2):119-123
pubmed: 30520715
Cell Biochem Biophys. 2014 Jan;68(1):207-10
pubmed: 23749559
Clin Infect Dis. 2015 Aug 1;61(3):418-26
pubmed: 25900174
J Antimicrob Chemother. 2015 Sep;70(9):2515-8
pubmed: 25995292
PLoS One. 2016 Sep 28;11(9):e0162924
pubmed: 27679992
J Clin Microbiol. 2013 Jul;51(7):2245-9
pubmed: 23658265
Pathogens. 2023 Mar 22;12(3):
pubmed: 36986417
Antimicrob Agents Chemother. 2015 Oct 12;60(1):52-6
pubmed: 26459899
Eur J Clin Microbiol Infect Dis. 2017 Sep;36(9):1565-1567
pubmed: 28361246
BMC Infect Dis. 2018 Dec 3;18(1):609
pubmed: 30509194
Clin Infect Dis. 2016 Feb 1;62(3):405-6
pubmed: 26494825
J Antimicrob Chemother. 2021 Mar 12;76(4):865-875
pubmed: 33367765
Pediatr Infect Dis J. 2001 Jul;20(7):679-84
pubmed: 11465840
J Infect Dis. 2017 Jul 15;216(suppl_2):S412-S419
pubmed: 28838073
Emerg Infect Dis. 2017 May;23(5):809-812
pubmed: 28418319
Semin Fetal Neonatal Med. 2009 Aug;14(4):190-9
pubmed: 19109084
Int J STD AIDS. 2013 Oct;24(10):822-8
pubmed: 24052013
J Antimicrob Chemother. 2017 Feb;72(2):330-337
pubmed: 27798207
Clin Infect Dis. 2015 Apr 15;60(8):1228-36
pubmed: 25537875
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1845-1851
pubmed: 29924422
Clin Infect Dis. 2018 Feb 10;66(5):796-798
pubmed: 29028993
Emerg Infect Dis. 2019 Apr;25(4):719-727
pubmed: 30882306
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32229497
Sex Transm Dis. 2020 Mar;47(3):199-201
pubmed: 32032318